|
|
|
|
|
|
|
12
Information Technology and Future Visions of Pharmaceutical Project Management |
|
|
|
|
|
|
|
|
Ian Trout, Paul H. Willer, Andrew J. M. Black, Helen Grant,
and Nick Edwards
Andersen Consulting
Manchester and London, England |
|
|
|
 |
|
|
|
|
I. Introduction |
|
|
|
| | |
|
|
|
|
II. Today's Use of Information Technology in Drug Development |
|
|
|
| | |
|
|
|
|
III. Major it Developments |
|
|
|
| | |
|
|
|
|
A. Integration |
|
|
|
| | |
|
|
|
|
B. Virtual Entities |
|
|
|
| | |
|
|
|
|
C. Interactive Reach |
|
|
|
| | |
|
|
|
|
IV. Future Visions of Drug Development |
|
|
|
| | |
|
|
|
|
A. Cross-Functional High-Performance Teams |
|
|
|
| | |
|
|
|
|
B. Globalization |
|
|
|
| | |
|
|
|
|
C. Virtual Organizations |
|
|
|
| | |
|
|
|
|
V. Future Visions of Pharmaceutical Project Management |
|
|
|
| |
|
|
|
|
|
Additional contributions from: Pradip Banerjee, Jan Paul Zonnenberg, Mary Jo Veverka, Gale Thompson, George Smith, Kay Renfrew, Patrick Howard, Anatole Gershman, David Hadley, Stephen Sato, Kishore Swaminathan, and Mark Edwards. |
|
|
|
|
|